Dermatologic Therapy最新文献

{"title":"Evaluation of a Novel Short-Contact Therapy With 4% Glycyrrhetinic Acid Complex Gel for Scalp Seborrheic Dermatitis: A Pre- and Postintervention Study","authors":"Chii-Shyan Wang,&nbsp;Hsiao-Chi Wang,&nbsp;Hsuan-Hsiang Chen","doi":"10.1155/dth/4298078","DOIUrl":"https://doi.org/10.1155/dth/4298078","url":null,"abstract":"<p><b>Background:</b> Scalp seborrheic dermatitis (SSD) is a chronic inflammatory dermatosis characterized by sebum imbalance and proliferation of <i>Malassezia</i> species. While various antifungal shampoos are commonly used to manage SSD, there remains a substantial demand for alternative treatments that provide a more rapid onset of action. Glycyrrhetinic acid is recognized for its antioxidative, anti-inflammatory, antimicrobial, and antiallergic properties. This study aimed to evaluate the efficacy of a novel scalp gel containing 4% glycyrrhetinic acid complex as a short-contact therapy for SSD.</p><p><b>Methods:</b> A total of 40 patients with SSD were enrolled in this study and treated with the 4% glycyrrhetinic acid complex gel using a short-contact therapy approach. Clinical efficacy was assessed by the Adherent Scalp Flaking Score (ASFS) and Dermatology Life Quality Index (DLQI) at baseline, Week 1, and Week 2, all evaluated by the same dermatologist. Treatment satisfaction was measured at Week 2 using the Treatment Satisfaction Questionnaire (TSQ).</p><p><b>Results:</b> Significant improvements in ASFS and DLQI were observed at both Week 1 and Week 2 compared to baseline. Patient satisfaction, as measured by the TSQ, yielded a mean score of 4.2 ± 0.8 on a 5-point scale.</p><p><b>Conclusions:</b> This study demonstrates the clinical efficacy of the novel 4% glycyrrhetinic acid complex scalp gel as a short-contact therapy for SSD. The rapid onset of action and significant improvement in symptoms suggest that this gel could serve as an effective alternative for managing SSD in the acute phase.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4298078","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144998608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Hydroxychloroquine Combined With Doxycycline for the Treatment of Patients With Rosacea: A Randomized, Double-Blind, Double-Dummy Clinical Trial","authors":"Xin Yuan,&nbsp;Jin Lu,&nbsp;Liang Sheng,&nbsp;Guang Shi,&nbsp;Xue Chen,&nbsp;Leiwei Jiang","doi":"10.1155/dth/6636265","DOIUrl":"https://doi.org/10.1155/dth/6636265","url":null,"abstract":"<p><b>Purpose:</b> While the 2021 Chinese rosacea guidelines recommend hydroxychloroquine (HCQ) and doxycycline as A-level treatments for erythema, monotherapy with these agents has shown suboptimal clinical efficacy against both erythema and flushing symptoms. This study aimed to evaluate whether combination therapy could enhance therapeutic outcomes without increasing adverse effects (AEs).</p><p><b>Methods:</b> In this randomized, double-blind, placebo-controlled trial conducted at Guizhou Provincial People’s Hospital (January 2022–January 2024), 73 moderate-to-severe rosacea patients were randomized to receive either (1) HCQ 200 mg bid plus doxycycline 100 mg qd (intervention group, <i>n</i> = 36) or (2) placebo plus doxycycline 100 mg qd (control group, <i>n</i> = 37). Treatment duration was 8 weeks with follow-up assessments at Weeks 0, 4, 8, and 12.</p><p><b>Results:</b> Among 58 completers (29 per group), the intervention group demonstrated significantly higher clinical efficacy at Week 8: erythema improvement rates (89.67% vs. 68.97%, <i>p</i> &lt; 0.05), flushing reduction (68.97% vs. 44.83%, <i>p</i> &lt; 0.05), and greater quality-of-life improvement (RosQoL score Δ23.66 vs. Δ17.00, <i>p</i> &lt; 0.05). Investigator’s Global Assessment showed comparable results (72.22% vs. 65%, <i>p</i> &gt; 0.05). Both regimens were well tolerated with no severe AEs reported.</p><p><b>Conclusion:</b> The HCQ–doxycycline combination demonstrates superior efficacy over doxycycline monotherapy for improving erythema, flushing symptoms, and quality of life in moderate-to-severe rosacea patients, with comparable safety profiles.</p><p><b>Trial Registration:</b> Chinese Clinical Trial Register: ChiCTR2400089784</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6636265","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144918642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparisons of Efficacy and Safety of Different Doses of Doxycycline for the Treatment of Moderate-to-Severe Acne Vulgaris: A Systematic Review and Network Meta-Analysis","authors":"Shuxian Shang,&nbsp;Fangzhi Du,&nbsp;Hua Feng,&nbsp;Yuelin Wu","doi":"10.1155/dth/1713121","DOIUrl":"https://doi.org/10.1155/dth/1713121","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Background:&lt;/b&gt; The evidence is insufficient for the administration of subantimicrobial doses of doxycycline in the treatment of acne vulgaris, and the results from the limited studies were inconsistent.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Objectives:&lt;/b&gt; This study aims to comprehensively compare the efficacy and safety of different doses of doxycycline for moderate-to-severe acne vulgaris.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Methods:&lt;/b&gt; A systematic review and network meta-analysis of randomized controlled trials were carried out. Literature was searched from PubMed (from inception to May 31, 2025), EMBASE (from inception to May 31, 2025), Cochrane Central Register of Controlled Trials (CENTRAL, from inception to May 31, 2025), Wanfang Data (from inception to May 11, 2025), and CNKI (from inception to May 11, 2025).The RCTs comparing the efficacy and safety of different doses of doxycycline in the treatment of acne vulgaris were included if they fulfilled the following inclusion criteria: (1) participants were adolescents or adults aged 12–60 years with moderate-to-severe acne vulgaris; (2) both interventions and controls were limited to different doses (0–200 mg/d) of doxycycline for different durations with or without the use of other systemic or topical drugs; and (3) outcomes at least included the changes in inflammatory skin lesions (papules, pustules, cysts, nodules, and so on) and the incidence of adverse events. Exclusion criteria were as follows: (1) duplicate records; (2) reviews, comments, meta-analysis, guideline/consensus, proceeding abstract, case reports, and thesis; (3) studies with unavailable outcomes or incomplete data; (4) studies whose participants, controls, design, outcomes, and intervention failed to meet the inclusion criteria; and (5) not in English or Chinese language. Risk of bias was independently evaluated by two reviewers separately using the version 2.0 of the Cochrane risk-of-bias tool for randomized trials (RoB 2.0). The pooled effects on continuous variables were summarized as standardized mean differences (SMDs), and those on the dichotomous variable as odds ratio (OR). Standard pairwise comparisons using both fixed and random effect models as well as network meta-analysis were carried out.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; Totally, 635 records were potentially relevant based on initial screening. After excluding duplicates and publications that did not meet the inclusion criteria, four English articles describing four RCTs with a total of 1070 participants were finally included. All the four included studies administered 40 mg/d of doxycycline, three studies administered placebo, two studies administered 100 mg/d of doxycycline, and one study administered 80 and 160 mg/d of doxycycline. As the network meta-analysis showed, for reduction of the count of inflammatory acne lesions, 40 mg/d of doxycycline was significantly more effective than that of placebo (&lt;i&gt;p&lt;/i&gt; = 0.03) but was insignificantly different from that of 80 mg/d (&lt;i&gt;p&lt;/i&gt; = 0.22), 100 mg/d (&lt;i&gt;p&lt;/i&gt; = ","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1713121","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144915004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Glycopyrronium Bromide 1% Cream in Axillary and Extra-Axillary Primary Hyperhidrosis: A Real-Life Two-Center Experience on 68 Subjects","authors":"Helena Gioacchini,&nbsp;Andrea Marani,&nbsp;Federico Diotallevi,&nbsp;Agnese Rossi,&nbsp;Sara Lambiase,&nbsp;Virginia Maffei,&nbsp;Luca Bianchi,&nbsp;Elena Campione,&nbsp;Anna Campanati","doi":"10.1155/dth/7069427","DOIUrl":"https://doi.org/10.1155/dth/7069427","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Introduction:&lt;/b&gt; Primary hyperhidrosis (PH) is a common disorder affecting approximately 1% of the general population, characterized by focal sweating in excess of that required for normal temperature regulation without any associated condition. It is an embarrassing and disabling condition with a great impact on patients’ quality of life. Glycopyrronium bromide (GPB) 1% cream is a recently authorized topical pharmacological treatment for primary axillary PH. Although the efficacy of this treatment for axillary hyperhidrosis is well established, there are no clinical data regarding both efficacy and safety of GPB 1% cream when used in other body areas such as palm, plantar, and craniofacial regions (out-of-label use).&lt;/p&gt;&lt;p&gt;&lt;b&gt;Materials and Methods:&lt;/b&gt; In this study, the real-life experience of two Italian tertiary center care dermatology clinics for treatment of PH with GPB 1% cream for both axillary and extra-axillary localizations has been reported. Patients suffering from PH were treated for 12 weeks. The treatment of the affected areas with GPB 1% cream consisted of once-daily application for 4 weeks (T4), followed by a reduced frequency of application over the following 8 weeks (T12). Main efficacy outcomes included assessment of change in the 4-point Hyperhidrosis Disease Severity Scale (HDSS) and the 36-point Hyperhidrosis Quality of Life Index (HidroQoL); axillary PH patients were also assessed for change in the 4-item Axillary Daily Sweating Diary (ASDD). Safety of use was assessed at both T4 and T12, through anamnestic collection of symptoms and direct patient observation.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; Patients with PH evaluated were 68 (39 female and 29 males with a mean age of 40 ± 16.0 years). Thirty-one subjects (45%) suffered from axillary PH, 10 subjects (15%) had multiple localizations (axilla and palmoplantar and axilla and craniofacial), 13 subjects showed only palmar involvement (19%), and 14 subjects experienced only craniofacial PH (21%). All subjects but 5 (7%) completed the 12-week treatment period. HDSS score before treatment was 3.54 ± 0.53, HidroQoL 27.874 ± 2.238.7, and ASDD (&lt;i&gt;n&lt;/i&gt; = 31) 13.66 ± 1.5. The mean HDSS value was reduced significantly to 1.1 ± 0.45 at T4 (&lt;i&gt;p&lt;/i&gt; = 0.001) and to 1.2 ± 0.50 at T12; the overall percentage of HDSS good responder patients (patients experiencing a reduction in HDSS of at least two points = reduction in sweating between 50% and 75% from baseline value) was 53% at T4 and 43% at T12, and the other patients were considered mild responders. HidroQoL was reduced to 8.18 ± 1.83(T4) and 9.05 ± 0.78 (T12) (&lt;i&gt;p&lt;/i&gt; = 0.001). As expected, GPB 1% cream was highly effective in subjects with axillary PH considering the reduction in ASDD score to 2.1 ± 0.57 and 2.2 ± 0.65 at T4 and T12, respectively (&lt;i&gt;p&lt;/i&gt; = 0.001). Considering the different localizations of hyperhidrosis separately, at T4, the percentage of patients experiencing a reduction in HDSS of at least two points was 76%, 30%,","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7069427","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144915005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogenic Mechanisms and Mechanism-Directed Therapies for Androgenetic Alopecia: Current Understanding and Future Directions","authors":"Huanyu Shi,&nbsp;Xiaolin Wang,&nbsp;Xueli Li,&nbsp;Yanyan Feng","doi":"10.1155/dth/9950475","DOIUrl":"https://doi.org/10.1155/dth/9950475","url":null,"abstract":"<p>Androgenetic alopecia (AGA) affects about half of men and many women worldwide, yet current treatments often fall short. This review summarizes key pathogenic mechanisms of AGA, centering on three interconnected processes: the dihydrotestosterone–prostaglandin D2 (DHT–PGD2) loop, oxidative stress and inflammation, and lipid metabolism dysregulation. These factors converge to suppress Wnt/β-catenin signaling, the core pathway for hair growth. DHT and PGD2 reinforce each other to drive follicular miniaturization via CXXC5 and GSK-3β activation. Oxidative stress and chronic inflammation—exacerbated by scalp microbiome imbalance, notably excess <i>Cutibacterium acnes</i> and Malassezia—further damage the follicular environment. Suppressed PPARγ signaling disrupts adipocyte-follicle crosstalk, reducing growth factor support. These insights reveal emerging therapeutic targets, including DP2 antagonists, CXXC5/GSK-3β inhibitors, antioxidants, microbiome modulators, and PPARγ agonists. By integrating molecular, microbial, and metabolic perspectives, this review outlines a framework for multitarget strategies to address the limitations of existing AGA treatments.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9950475","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144905492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese Herbal Medicine for Atopic Dermatitis: A Systematic Review of Registered Randomised Controlled Trials","authors":"Meaghan E. Coyle,&nbsp;Junfeng Liu,&nbsp;Anthony L. Zhang,&nbsp;Xinfeng Guo,&nbsp;Dacan Chen,&nbsp;Charlie C. Xue","doi":"10.1155/dth/9920370","DOIUrl":"https://doi.org/10.1155/dth/9920370","url":null,"abstract":"<p><b>Background and Purpose:</b> Many people with atopic dermatitis seek treatment with Chinese herbal medicine (CHM). However, the evidence that informed clinical guideline recommendations is outdated. This research updates the evidence on the efficacy and safety of CHM for atopic dermatitis and supports clinical decision-making.</p><p><b>Methods:</b> Randomised controlled trials (RCTs) were identified from the World Health Organization’s International Clinical Trials Registry Platform. RCTs that compared CHM with a placebo, waitlist control or conventional medicine were eligible if they reported patient-reported outcomes, clinician-reported symptoms, long-term control, health-related quality of life or safety. Characteristics and results were extracted, risk of bias assessed and the certainty of evidence determined using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Meta-analysis was conducted where possible.</p><p><b>Results:</b> Seven RCTs (862 participants) were included. Topical CHM was not statistically different to placebo in reducing visual analogue scale itch score (MD −2.15 [−5.64, 1.34], <i>I</i>² = 95%; evidence not graded) but was more effective than placebo in reducing Eczema Area and Severity Index scores (MD −2.75 [−4.07, −1.44], <i>I</i>² = 0%; low certainty evidence). CHM was not statistically different to placebo in improving health-related quality of life (MD −2.20 [−5.27, 0.88], <i>I</i>² = 0%; moderate certainty evidence). More adverse events were reported in the CHM groups than in the comparator groups.</p><p><b>Conclusion:</b> There is limited evidence to support a change in clinical practice using CHM for atopic dermatitis. Future research should focus on patient-reported symptoms and clinician-reported signs and should carefully assess adverse events.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9920370","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144881322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, Histopathological, and Direct Immunofluorescence Characteristics of Prurigo-Nodularis-Like Lesions and Pruritus: A Retrospective Study of Patients Admitted to a Tertiary Dermatology Hospital","authors":"Sajedeh Rezaeemanesh,&nbsp;Mehrdad Fathikazerouni,&nbsp;Nasim Tootoonchi,&nbsp;Alireza Ghanadan,&nbsp;Seyed Mohammad Vahabi,&nbsp;Sahar Montazeri,&nbsp;Huria Memari,&nbsp;Ifa Etesami","doi":"10.1155/dth/6375115","DOIUrl":"https://doi.org/10.1155/dth/6375115","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Prurigo nodularis (PN) is a chronic skin condition characterized by intensely itchy nodules. Accurate identification and treatment of PN-like lesions are crucial due to their association with various dermatoses. Direct immunofluorescence (DIF) assays play a significant role in distinguishing PN from similar conditions.</p>\u0000 <p><b>Methods:</b> We conducted a retrospective analysis on patients referred to a tertiary dermatology hospital between 2017 and 2022. These patients presented with pruritus and PN-like lesions and underwent skin biopsies. PN diagnosis relied on clinical evidence, laboratory results, and histopathology, ruling out other differentials. Collected data included demographics, clinical manifestations, histology, and final diagnoses. Statistical analysis employed SPSS Version 26, using mean, standard deviation, frequency, and percentage. Significance was set at <i>p</i> &lt; 0.05.</p>\u0000 <p><b>Results:</b> Our study included 746 individuals (mean age 45.34 ± 22.05; 423 females and 323 males) with pruritus and PN-like lesions. Clinical evidence and laboratory findings established final diagnoses: PN (51.1%), dermatitis (17.6%), lichen planus (8.4%), perforating disease (7.0%), and bite reaction (3.1%). DIF assays were performed on 177 patients, with 26 (19.2%) yielding positive results. Bullous pemphigoid (50%) and dermatitis herpetiformis (11.5%) were the most common diagnoses.</p>\u0000 <p><b>Conclusion:</b> Our study emphasizes the need for comprehensive diagnostic approaches, including DIF, to accurately diagnose PN-related conditions. The high PN confirmation rate validates initial clinical suspicion and expert judgment. Considering the potential confusion with dermatitis and immunobullous disorders, targeted health policies and resource allocation are essential for improved diagnostic capabilities and treatment outcomes in patients with PN-like lesions.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6375115","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144758518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Topical Famotidine Combined With Thulium 1927 nm Fractional Laser in the Treatment of Melasma: A Split-Face Randomized, Single-Blind, Vehicle-Controlled Clinical Trial With Long-Term Follow-Up","authors":"Shujuan He,&nbsp;Dan Ye,&nbsp;Simeng Qiao,&nbsp;Luyue Zhang,&nbsp;Xi Zhao,&nbsp;Yuxin Zhang,&nbsp;Jing Liu,&nbsp;Weihui Zeng,&nbsp;Zhao Wang","doi":"10.1155/dth/9979632","DOIUrl":"https://doi.org/10.1155/dth/9979632","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Melasma is a common hyperpigmentation skin disorder with a high recurrence rate. Mast cell activation plays a role in its pathogenesis, with melanocyte activation via histamine receptor 2 (H2R) considered a potential mechanism. This study aims to evaluate the efficacy of topical famotidine combined with 1927 nm thulium fractional laser in treating melasma and reducing recurrence.</p>\u0000 <p><b>Methods:</b> The study was designed as a split-face, randomized-controlled, single-blind trial. Participants underwent four full-face 1927 nm fractional laser treatments at 4-week intervals and applied 2% famotidine solution on a randomly assigned side and control solution on the opposite side of the face twice daily for 16 weeks. Skin assessments including VISIA imaging, modified melasma area severity index (mMASI) score, and DermaLab skin color detection were conducted by blinded dermatologists at Weeks 0, 4, 8, 12, and 16. Self-assessment scores and the melasma quality of life (MELASQoL) index were collected at baseline and Week 16. Long-term follow-up was performed at Week 64. All side effects were recorded. Statistical analyses included paired <i>t</i>-tests, repeated measures ANOVA, and Wilcoxon and Friedman tests.</p>\u0000 <p><b>Results:</b> A total of 16 patients were enrolled in the study. At Week 16, the famotidine-treated side showed significant reductions in mMASI (<i>p</i> = 0.019, <span></span><math></math> = 0.598) and melanin index (MI) (<i>p</i> = 0.006, <span></span><math></math> = 0.672), with a slight improvement in erythema index (EI). ∆MI was significantly lower on the famotidine-treated side than the control (<i>p</i> = 0.012, Cohen’s d = 0.710). Both MELASQoL scores and patient self-assessments improved, with no obvious adverse effects observed. Long-term evaluation at Week 64 revealed sustained improvement in mMASI on the famotidine-treated side compared to the control side (<i>p</i> = 0.029, Cohen’s d = 0.686).</p>\u0000 <p><b>Conclusions:</b> This study provides clinical evidence supporting H2R blockade as a potential melasma treatment. Famotidine may enhance laser efficacy and modulate histamine-mediated melanogenesis, offering long-term benefits in reducing recurrence.</p>\u0000 <p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT06313307</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9979632","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144550993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-Induced Eyelid Edema: A Systematic Review","authors":"J. Tartaglia,&nbsp;I. Tudurachi,&nbsp;F. Cassalia,&nbsp;L. Gnesotto,&nbsp;D. G. Boemo,&nbsp;S. Piaserico","doi":"10.1155/dth/5577128","DOIUrl":"https://doi.org/10.1155/dth/5577128","url":null,"abstract":"<div>\u0000 <p>Eyelid edema is a common clinical presentation with multiple etiologies, some of which can pose life-threatening risks to patients. Isolated eyelid edema, without additional significant signs or symptoms, presents a diagnostic challenge. A growing number of drugs are associated with the development of eyelid edema, particularly new-generation small molecules. To identify the most frequently implicated drugs in this clinical scenario, we conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. Forty-three studies met the inclusion criteria, identifying the drug groups most frequently associated with isolated eyelid edema: mammalian target of rapamycin (mTOR) inhibitors (sirolimus and everolimus), atypical antipsychotics (clozapine, risperidone, and olanzapine), fillers (hyaluronic acid and polyalkylimide), and oncologic drugs (imatinib and pemetrexed). The epidemiological characteristics of the patients in each group were highly variable and reflected the use of the aforementioned drugs in heterogeneous populations. The response to eyelid edema treatments also varied significantly. Patients with eyelid edema induced by atypical antipsychotics showed the highest response to conservative therapy, with a 100 percent response following either dose reduction or drug discontinuation. On the other hand, the response to conservative treatments for eyelid edema caused by oncologic drugs was inconsistent, with cases of persistent edema even after drug cessation. In these cases, blepharoplasty proved to be an effective and long-lasting solution. Lastly, in most filler-induced cases, an excellent response was observed following treatment with intralesional hyaluronidase.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5577128","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144550992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effectiveness and Safety of Three Treatment Regimens of Topical Minoxidil 5.0%, Betamethasone 0.064% w/w, and Castor and Jojoba Oils for Alopecia Areata: A Multicenter Cohort Study","authors":"Amir Abadi,&nbsp;Wala Abdeljawad,&nbsp;Emad Khatib,&nbsp;Shorok Jaber,&nbsp;Sari Taha,&nbsp;Munther Ardah,&nbsp;Manal Ardah,&nbsp;Basma Damiri","doi":"10.1155/dth/6631359","DOIUrl":"https://doi.org/10.1155/dth/6631359","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> Alopecia areata (AA) is a chronic, remitting–relapsing dermatological disease that is associated with a substantial psychological impact. Despite the availability of a wide range of therapeutic options, none provides a cure for AA. This study aimed to compare the effectiveness of topical betamethasone as a monotherapy with combinations of topical betamethasone with either topical minoxidil 5% or a herbal preparation of castor and jojoba oils.</p>\u0000 <p><b>Methods:</b> This was a multicenter, cohort study in which patients diagnosed with AA were taking one of three treatment regimens: a reference monotherapy of topical betamethasone 0.064% w/w; combined topical minoxidil and betamethasone 0.064% w/w; or combined topical betamethasone 0.064% w/w and a herbal preparation of castor and jojoba oils. The data were collected at the beginning of the study using a questionnaire. Patients were assessed at three follow-up visits for hair regrowth using trichoscopy as the primary outcome. Patient satisfaction and compliance were assessed using 10-point scales.</p>\u0000 <p><b>Results:</b> The final sample consisted of 278 patients. Combined topical minoxidil–betamethasone therapy was significantly associated with higher rates of hair regrowth (<i>p</i> = 0.006), patient satisfaction (<i>p</i> &lt; 0.001), and shorter median time to first improvement (<i>p</i> &lt; 0.001). Combined minoxidil/betamethasone was more likely to achieve hair regrowth than the other two treatments at the multivariate level (aRR = 2.239, CI = 1.153–4.347). Moreover, hair regrowth was significantly different between the treatment groups after each phase, with hair regrowth at the final phase observed in 83.2% of patients using combined topical minoxidil and betamethasone.</p>\u0000 <p><b>Conclusions:</b> The use of topical minoxidil–betamethasone combination for AA was superior to betamethasone monotherapy or combined with herbal preparations. Randomized clinical trials are needed to strengthen the evidence.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6631359","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}